ID   GLRX2_HUMAN             Reviewed;         164 AA.
AC   Q9NS18; Q3LR69; Q7L1N7; Q96JC0; Q9Y3D4;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 147.
DE   RecName: Full=Glutaredoxin-2, mitochondrial;
DE   Flags: Precursor;
GN   Name=GLRX2; Synonyms=GRX2; ORFNames=CGI-133;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Colon, and Testis;
RX   PubMed=11297543; DOI=10.1074/jbc.M011605200;
RA   Lundberg M., Johansson C., Chandra J., Enoksson M., Jacobsson G.,
RA   Ljung J., Johansson M., Holmgren A.;
RT   "Cloning and expression of a novel human glutaredoxin (Grx2) with
RT   mitochondrial and nuclear isoforms.";
RL   J. Biol. Chem. 276:26269-26275(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11397793; DOI=10.1074/jbc.M100020200;
RA   Gladyshev V.N., Liu A., Novoselov S.V., Krysan K., Sun Q.-A.,
RA   Kryukov V.M., Kryukov G.V., Lou M.F.;
RT   "Identification and characterization of a new mammalian glutaredoxin
RT   (thioltransferase), Grx2.";
RL   J. Biol. Chem. 276:30374-30380(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLU-95.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4-164 (ISOFORM 1).
RX   PubMed=10810093; DOI=10.1101/gr.10.5.703;
RA   Lai C.-H., Chou C.-Y., Ch'ang L.-Y., Liu C.-S., Lin W.-C.;
RT   "Identification of novel human genes evolutionarily conserved in
RT   Caenorhabditis elegans by comparative proteomics.";
RL   Genome Res. 10:703-713(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4-164 (ISOFORM 1).
RC   TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=15184054; DOI=10.1016/j.bbrc.2004.04.199;
RA   Lundberg M., Fernandes A.P., Kumar S., Holmgren A.;
RT   "Cellular and plasma levels of human glutaredoxin 1 and 2 detected by
RT   sensitive ELISA systems.";
RL   Biochem. Biophys. Res. Commun. 319:801-809(2004).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=15297967; DOI=10.1016/j.humpath.2004.04.009;
RA   Peltoniemi M., Kaarteenaho-Wiik R., Saily M., Sormunen R., Paakko P.,
RA   Holmgren A., Soini Y., Kinnula V.L.;
RT   "Expression of glutaredoxin is highly cell specific in human lung and
RT   is decreased by transforming growth factor-beta in vitro and in
RT   interstitial lung diseases in vivo.";
RL   Hum. Pathol. 35:1000-1007(2004).
RN   [9]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF SER-78 AND
RP   CYS-80.
RX   PubMed=14676218; DOI=10.1074/jbc.M312719200;
RA   Johansson C., Lillig C.H., Holmgren A.;
RT   "Human mitochondrial glutaredoxin reduces S-glutathionylated proteins
RT   with high affinity accepting electrons from either glutathione or
RT   thioredoxin reductase.";
RL   J. Biol. Chem. 279:7537-7543(2004).
RN   [10]
RP   FUNCTION.
RX   PubMed=15328416; DOI=10.1073/pnas.0401896101;
RA   Lillig C.H., Loenn M.E., Enoksson M., Fernandes A.P., Holmgren A.;
RT   "Short interfering RNA-mediated silencing of glutaredoxin 2 increases
RT   the sensitivity of HeLa cells toward doxorubicin and phenylarsine
RT   oxide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:13227-13232(2004).
RN   [11]
RP   FUNCTION.
RX   PubMed=15649413; DOI=10.1016/j.bbrc.2004.12.067;
RA   Enoksson M., Fernandes A.P., Prast S., Lillig C.H., Holmgren A.,
RA   Orrenius S.;
RT   "Overexpression of glutaredoxin 2 attenuates apoptosis by preventing
RT   cytochrome c release.";
RL   Biochem. Biophys. Res. Commun. 327:774-779(2005).
RN   [12]
RP   SUBUNIT, ENZYME REGULATION, METAL-BINDING, AND MUTAGENESIS OF CYS-68
RP   AND CYS-153.
RX   PubMed=15917333; DOI=10.1073/pnas.0500735102;
RA   Lillig C.H., Berndt C., Vergnolle O., Loenn M.E., Hudemann C.,
RA   Bill E., Holmgren A.;
RT   "Characterization of human glutaredoxin 2 as iron-sulfur protein: a
RT   possible role as redox sensor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:8168-8173(2005).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   STRUCTURE BY NMR OF 48-164.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of RSGI RUH-044, an N-terminal 2 domain of
RT   glutaredoxin 2 from human cDNA.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 50-164 IN COMPLEX WITH
RP   GLUTATHIONE, GLUTATHIONYLATION AT CYS-77, AND DISULFIDE BOND.
RX   PubMed=17121859; DOI=10.1074/jbc.M608179200;
RA   Johansson C., Kavanagh K.L., Gileadi O., Oppermann U.;
RT   "Reversible sequestration of active site cysteines in a 2Fe-2S-bridged
RT   dimer provides a mechanism for glutaredoxin 2 regulation in human
RT   mitochondria.";
RL   J. Biol. Chem. 282:3077-3082(2007).
CC   -!- FUNCTION: Glutathione-dependent oxidoreductase that facilitates
CC       the maintenance of mitochondrial redox homeostasis upon induction
CC       of apoptosis by oxidative stress. Involved in response to hydrogen
CC       peroxide and regulation of apoptosis caused by oxidative stress.
CC       Acts as a very efficient catalyst of monothiol reactions because
CC       of its high affinity for protein glutathione-mixed disulfides. Can
CC       receive electrons not only from glutathione (GSH), but also from
CC       thioredoxin reductase supporting both monothiol and dithiol
CC       reactions. Efficiently catalyzes both glutathionylation and
CC       deglutathionylation of mitochondrial complex I, which in turn
CC       regulates the superoxide production by the complex. Overexpression
CC       decreases the susceptibility to apoptosis and prevents loss of
CC       cardiolipin and cytochrome c release.
CC       {ECO:0000269|PubMed:11297543, ECO:0000269|PubMed:14676218,
CC       ECO:0000269|PubMed:15328416, ECO:0000269|PubMed:15649413}.
CC   -!- ENZYME REGULATION: The 2Fe-2S present in the homodimer leads to
CC       inactivation of the enzyme. The 2Fe-2S may serve as a redox
CC       sensor: the presence of one-electron oxidants or reductants
CC       leading to the loss of the 2Fe-2S cluster, subsequent
CC       monomerization and activation of the enzyme. Unlike other
CC       glutaredoxins, it is not inhibited by oxidation of structural Cys
CC       residues. {ECO:0000269|PubMed:15917333}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=5.9 mM for GSH {ECO:0000269|PubMed:14676218};
CC         KM=0.77 mM for glutathionylated ribonuclease A
CC         {ECO:0000269|PubMed:14676218};
CC         KM=4.3 mM for glutathionylated BSA
CC         {ECO:0000269|PubMed:14676218};
CC         KM=0.11 mM for glutathionylated beta-mercaptoethanol
CC         {ECO:0000269|PubMed:14676218};
CC   -!- SUBUNIT: Monomer; active form. Homodimer; inactive form. The
CC       homodimer is probably linked by 1 2Fe-2S cluster.
CC       {ECO:0000269|PubMed:15917333, ECO:0000269|PubMed:17121859}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Mitochondrion.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Grx2a;
CC         IsoId=Q9NS18-1; Sequence=Displayed;
CC       Name=2; Synonyms=Grx2b;
CC         IsoId=Q9NS18-2; Sequence=VSP_015221;
CC         Note=Variant in position: 40:R->W.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Expressed in brain, heart,
CC       skeletal muscle, colon, thymus, spleen, kidney, liver, small
CC       intestine, placenta and lung. Not expressed in peripheral blood
CC       leukocytes. {ECO:0000269|PubMed:11297543,
CC       ECO:0000269|PubMed:15184054, ECO:0000269|PubMed:15297967}.
CC   -!- MISCELLANEOUS: The absence of GLRX2 dramatically sensitizes cells
CC       to cell death induced by doxorubicin/adriamycin and phenylarsine
CC       oxide.
CC   -!- SIMILARITY: Belongs to the glutaredoxin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD34128.1; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
CC       Sequence=AAH28113.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/glrx2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF132495; AAF37320.2; -; mRNA.
DR   EMBL; AF290514; AAK83089.1; -; mRNA.
DR   EMBL; AY038988; AAK72499.1; -; mRNA.
DR   EMBL; DQ194815; ABA03170.1; -; Genomic_DNA.
DR   EMBL; AL136370; CAI10820.1; -; Genomic_DNA.
DR   EMBL; AL136370; CAI10821.1; -; Genomic_DNA.
DR   EMBL; AF151891; AAD34128.1; ALT_FRAME; mRNA.
DR   EMBL; BC028113; AAH28113.1; ALT_INIT; mRNA.
DR   CCDS; CCDS1380.1; -. [Q9NS18-2]
DR   CCDS; CCDS1381.1; -. [Q9NS18-1]
DR   RefSeq; NP_001230328.1; NM_001243399.1.
DR   RefSeq; NP_001306220.1; NM_001319291.1.
DR   RefSeq; NP_057150.2; NM_016066.4. [Q9NS18-2]
DR   RefSeq; NP_932066.1; NM_197962.2. [Q9NS18-1]
DR   RefSeq; XP_016856886.1; XM_017001397.1.
DR   UniGene; Hs.458283; -.
DR   PDB; 2CQ9; NMR; -; A=48-164.
DR   PDB; 2FLS; X-ray; 2.05 A; A=56-164.
DR   PDB; 2HT9; X-ray; 1.90 A; A/B=41-164.
DR   PDBsum; 2CQ9; -.
DR   PDBsum; 2FLS; -.
DR   PDBsum; 2HT9; -.
DR   ProteinModelPortal; Q9NS18; -.
DR   SMR; Q9NS18; -.
DR   BioGrid; 119228; 6.
DR   IntAct; Q9NS18; 2.
DR   DrugBank; DB00143; Glutathione.
DR   iPTMnet; Q9NS18; -.
DR   PhosphoSitePlus; Q9NS18; -.
DR   BioMuta; GLRX2; -.
DR   DMDM; 73919686; -.
DR   EPD; Q9NS18; -.
DR   MaxQB; Q9NS18; -.
DR   PeptideAtlas; Q9NS18; -.
DR   PRIDE; Q9NS18; -.
DR   Ensembl; ENST00000367439; ENSP00000356409; ENSG00000023572. [Q9NS18-1]
DR   Ensembl; ENST00000367440; ENSP00000356410; ENSG00000023572. [Q9NS18-2]
DR   GeneID; 51022; -.
DR   KEGG; hsa:51022; -.
DR   UCSC; uc001gsz.3; human. [Q9NS18-1]
DR   CTD; 51022; -.
DR   DisGeNET; 51022; -.
DR   GeneCards; GLRX2; -.
DR   HGNC; HGNC:16065; GLRX2.
DR   HPA; HPA023087; -.
DR   HPA; HPA057224; -.
DR   MIM; 606820; gene.
DR   neXtProt; NX_Q9NS18; -.
DR   OpenTargets; ENSG00000023572; -.
DR   PharmGKB; PA28732; -.
DR   GeneTree; ENSGT00390000003677; -.
DR   HOGENOM; HOG000095204; -.
DR   HOVERGEN; HBG096801; -.
DR   InParanoid; Q9NS18; -.
DR   KO; K03676; -.
DR   OMA; SCSVRAM; -.
DR   OrthoDB; EOG091G0WLY; -.
DR   PhylomeDB; Q9NS18; -.
DR   TreeFam; TF319627; -.
DR   SABIO-RK; Q9NS18; -.
DR   EvolutionaryTrace; Q9NS18; -.
DR   GeneWiki; GLRX2; -.
DR   GenomeRNAi; 51022; -.
DR   PRO; PR:Q9NS18; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000023572; -.
DR   CleanEx; HS_GLRX2; -.
DR   Genevisible; Q9NS18; HS.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0051537; F:2 iron, 2 sulfur cluster binding; IEA:UniProtKB-KW.
DR   GO; GO:0008794; F:arsenate reductase (glutaredoxin) activity; TAS:UniProtKB.
DR   GO; GO:0009055; F:electron carrier activity; NAS:UniProtKB.
DR   GO; GO:0015038; F:glutathione disulfide oxidoreductase activity; TAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003756; F:protein disulfide isomerase activity; TAS:UniProtKB.
DR   GO; GO:0015035; F:protein disulfide oxidoreductase activity; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; NAS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; NAS:UniProtKB.
DR   GO; GO:0045454; P:cell redox homeostasis; TAS:UniProtKB.
DR   GO; GO:0071451; P:cellular response to superoxide; IEA:Ensembl.
DR   GO; GO:0042262; P:DNA protection; NAS:UniProtKB.
DR   GO; GO:0006749; P:glutathione metabolic process; TAS:UniProtKB.
DR   GO; GO:0009966; P:regulation of signal transduction; NAS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IDA:UniProtKB.
DR   GO; GO:0010033; P:response to organic substance; IDA:UniProtKB.
DR   GO; GO:0051775; P:response to redox state; TAS:UniProtKB.
DR   GO; GO:0009266; P:response to temperature stimulus; NAS:UniProtKB.
DR   InterPro; IPR002109; Glutaredoxin.
DR   InterPro; IPR011899; Glutaredoxin_euk/vir.
DR   InterPro; IPR014025; Glutaredoxin_subgr.
DR   InterPro; IPR012336; Thioredoxin-like_fold.
DR   Pfam; PF00462; Glutaredoxin; 1.
DR   PRINTS; PR00160; GLUTAREDOXIN.
DR   SUPFAM; SSF52833; SSF52833; 1.
DR   TIGRFAMs; TIGR02180; GRX_euk; 1.
DR   PROSITE; PS51354; GLUTAREDOXIN_2; 1.
PE   1: Evidence at protein level;
KW   2Fe-2S; 3D-structure; Alternative splicing; Complete proteome;
KW   Disulfide bond; Electron transport; Glutathionylation; Iron;
KW   Iron-sulfur; Metal-binding; Mitochondrion; Nucleus; Phosphoprotein;
KW   Polymorphism; Redox-active center; Reference proteome;
KW   Transit peptide; Transport.
FT   TRANSIT       1     19       Mitochondrion. {ECO:0000255}.
FT   CHAIN        20    164       Glutaredoxin-2, mitochondrial.
FT                                /FTId=PRO_0000011628.
FT   DOMAIN       57    157       Glutaredoxin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00686}.
FT   METAL        68     68       Iron-sulfur (2Fe-2S); shared with dimeric
FT                                partner; in inactive form. {ECO:0000305}.
FT   METAL       153    153       Iron-sulfur (2Fe-2S); shared with dimeric
FT                                partner; in inactive form. {ECO:0000305}.
FT   BINDING      74     74       Glutathione.
FT                                {ECO:0000269|PubMed:17121859}.
FT   BINDING     109    109       Glutathione.
FT                                {ECO:0000269|PubMed:17121859}.
FT   BINDING     121    121       Glutathione; via amide nitrogen and
FT                                carbonyl oxygen.
FT                                {ECO:0000269|PubMed:17121859}.
FT   MOD_RES      20     20       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      77     77       S-glutathionyl cysteine; alternate.
FT                                {ECO:0000269|PubMed:17121859}.
FT   DISULFID     77     80       Redox-active; alternate. {ECO:0000250}.
FT   VAR_SEQ       1     40       MIWRRAALAGTRLVWSRSGSAGWLDRAAGAAGAAAAAASG
FT                                -> MNPRDKQVSRFSPLKDVYTWVALAGIQRSGSPGRTRSA
FT                                ARR (in isoform 2).
FT                                {ECO:0000303|PubMed:11297543}.
FT                                /FTId=VSP_015221.
FT   VARIANT      95     95       K -> E (in dbSNP:rs34237236).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025234.
FT   MUTAGEN      68     68       C->S: Abolishes absorption at 320 nm and
FT                                420 nm suggesting the loss of 2Fe-2S-
FT                                binding. {ECO:0000269|PubMed:15917333}.
FT   MUTAGEN      78     78       S->P: Specifically increases the specific
FT                                activity but decreases affinity for
FT                                glutathionylated substrates.
FT                                {ECO:0000269|PubMed:14676218}.
FT   MUTAGEN      80     80       C->S: Strongly impairs enzymatic
FT                                activity. {ECO:0000269|PubMed:14676218}.
FT   MUTAGEN     153    153       C->S: Abolishes absorption at 320 nm and
FT                                420 nm suggesting the loss of 2Fe-2S-
FT                                binding. {ECO:0000269|PubMed:15917333}.
FT   HELIX        57     66       {ECO:0000244|PDB:2HT9}.
FT   STRAND       68     73       {ECO:0000244|PDB:2HT9}.
FT   HELIX        78     90       {ECO:0000244|PDB:2HT9}.
FT   STRAND       95     98       {ECO:0000244|PDB:2HT9}.
FT   HELIX        99    101       {ECO:0000244|PDB:2HT9}.
FT   HELIX       105    116       {ECO:0000244|PDB:2HT9}.
FT   STRAND      123    126       {ECO:0000244|PDB:2HT9}.
FT   STRAND      129    133       {ECO:0000244|PDB:2HT9}.
FT   HELIX       134    142       {ECO:0000244|PDB:2HT9}.
FT   HELIX       146    152       {ECO:0000244|PDB:2HT9}.
FT   STRAND      154    156       {ECO:0000244|PDB:2CQ9}.
FT   HELIX       160    162       {ECO:0000244|PDB:2HT9}.
SQ   SEQUENCE   164 AA;  18052 MW;  D9798A01BB532A5D CRC64;
     MIWRRAALAG TRLVWSRSGS AGWLDRAAGA AGAAAAAASG MESNTSSSLE NLATAPVNQI
     QETISDNCVV IFSKTSCSYC TMAKKLFHDM NVNYKVVELD LLEYGNQFQD ALYKMTGERT
     VPRIFVNGTF IGGATDTHRL HKEGKLLPLV HQCYLKKSKR KEFQ
//
